Glia maturation factor beta (GMFB)

Glia maturation factor beta (GMFB) is a highly conserved, 17 kDa intracellular protein composed of 142 amino acids, originally isolated from bovine and human brain[1][2][4]. GMFB belongs to the actin depolymerization factor homology (ADF-H) protein family and is primarily expressed in the central nervous system but also found in peripheral tissues such as kidney, thymus, and colon[1][2][4]. It functions as an intracellular regulator of the actin cytoskeleton, mainly by interacting with the Arp2/3 complex and facilitating the debranching of actin filament networks without direct binding to actin itself[3]. Beyond its structural role, GMFB acts as a neurotrophic factor implicated in nervous system development, growth and differentiation of glia and neurons, and modulation of inflammation and angiogenesis[1][4]. It influences various signaling pathways (p38 MAPK, ERK1/2, JAK-STAT, NF-κB) and regulates expression of cytokines such as IL-33 and TNF-α in astrocytes[1][3]. GMFB upregulation has been noted in Alzheimer's and Parkinson's diseases, as well as in diabetic complications such as retinopathy and osteoporosis, making it a candidate biomarker and potential drug target[3]. The small-molecule inhibitor DS-30 is the first described compound to specifically target GMFB by interfering with its interaction with the Arp2/3 complex, showing disease-modifying effects in preclinical models[3].

Other names

GMF-betaGMFglia maturation factor betaGMFB

GMFB modulates the actin cytoskeleton via Arp2/3 complex debranching, induces pro-inflammatory cytokine release (e.g., IL-33, TNF-α) from astrocytes, and regulates signaling pathways including p38 MAPK, ERK1/2, JAK-STAT, and NF-κB.